Prospective exploratory study to assess the safety and efficacy of aflibercept in cystoid macular oedema associated with retinitis pigmentosa

AIMS: To report the safety and efficacy of intravitreal aflibercept (Eylea) (ivA) for retinitis pigmentosa-associated cystoid macular oedema (RP-CMO) at 12 months via mean central macular thickness (CMT) and reported adverse events. METHODS: A prospective, exploratory, phase II, non-randomised, sing...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Ophthalmol
Asıl Yazarlar: Strong, Stacey A, Peto, Tunde, Bunce, Catey, Xing, Wen, Georgiou, Michalis, Esposti, Simona Degli, Kalitzeos, Angelos, Webster, Andrew, Michaelides, Michel
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2020
Konular:
Clinical Science
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7577098/
https://ncbi.nlm.nih.gov/pubmed/32041720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bjophthalmol-2019-315152
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller